Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-08-30

Study Completion Date

2022-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators aim to use comparative exome and/or genome sequencing to discover causative molecular lesions for phenotypes hypothesized to be caused by somatic mutations. For this study, investigators have targeted hypertrophic cardiomyopathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adult Patients With Undiagnosed Conditions and Their Responses to Clinically Uncertain Results From Exome Sequencing

NCT03605004

Undiagnosed Disease

COMPLETED

ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study

NCT00410241

Healthy Volunteers Atherosclerotic Heart Disease

ACTIVE_NOT_RECRUITING

Genetic Predictors of Outcome in HCM Patients

NCT00156429

Hypertrophic Cardiomyopathy

TERMINATED

A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare

NCT01736566

Healthy Adults (Full Study and Extension Phase) Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy

COMPLETED NA

Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions

NCT02077894

Genetic Eye Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The hypothesis is that sporadic or simplex occurrences of what are typically autosomal dominantly inherited diseases can instead be caused my mosaic mutations, specifically, mutations in the heart itself.

This hypothesis mandates that investigators sequence both affected and unaffected tissues, which in this case, investigators will construe to be peripheral blood DNA and discarded myocardium from cardiac procedures.

Eligible individuals will first undergo informed consent to be part of the study prior to their scheduled myomectomy. The study participants will also have phlebotomy for research samples.

The NIH Intramural Sequencing Center (NISC) will perform paired exome or genome sequencing and we will first screen for germline mutations in known cardiomyopathy genes that meet ACMG standards of likely pathogenic or pathogenic.

Then, if this is negative, investigators will screen for sequence variants that are present in cardiac tissue but absent in the blood DNA. Investigators will also screen blood DNA for secondary findings in genes recommended for annotation and results return by the ACMG and sequence variants deemed clinically relevant in this gene set will be validated in a CLIA-certified laboratory and the results returned to that participant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Cardiomyopathy Genetic Disease Gene Product Sequence Variation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genomic sequencing

Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures

Genomic sequencing

Intervention Type GENETIC

Genomic sequencing of DNA in Blood sample and myectomy tissue

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genomic sequencing

Genomic sequencing of DNA in Blood sample and myectomy tissue

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is 18 years and older has a clinical diagnosis of hypertrophic cardiomyopathy.
* Patient scheduled for clinically-indicated myomectomy.
* Patient has a negative family history of hypertrophic cardiomyopathy
* Patient is willing to receive results of secondary variant screen